| Budget Amount *help |
¥2,500,000 (Direct Cost: ¥2,500,000)
Fiscal Year 1992: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 1991: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1990: ¥1,100,000 (Direct Cost: ¥1,100,000)
|
|---|
| Research Abstract |
(1)To establish the effective chemotherapy regimen for patients with cervical adenocarcinoma, 15 conventional antitumordrugs were tested for their anticellular effects on 5 cervical adenocarcinoma cell lines. In addition to interferon-, etoposide(VP-16) and mitomycin C(MMC) were considered to be the best drugs for combination chemotherapy for cervical adenocarcinoma cell lines.
(2) Among the five adenocarcinoma cell lines, HPV 18 DNA was detected in four cell lines, however, none of the HPV DNA was detected in one cell line(OMC-4). Furthermore, a point mutation of p53 gene was demonstrated in this cell line, while no abnormality was observed in the remaining 4 cell lines.
(3) Thirty-two cervical adenocarcinomas and adenosequamous carcinomas were examined to search for human papillomaviruses using polymerase chain reaction system. HPV 16 and HPV 18 DNAs were detected in 22% and 16% of these carcinomas, respectively.
(4) Experiments using nude mice bearing transplanted cervical adenocarcinoma cell lines revealed that interferon-, VP-16, and MMC were effective against tumors in vivo both by single agent and by combination of these.
(5) Clinical trial by combination of 3 antitumor agents, CDDP, VP-16, and MMC, is now on going for the treatment of patients with cervical adenocarcinoma.
|
